期刊
JOURNAL OF GASTROENTEROLOGY
卷 52, 期 2, 页码 129-140出版社
SPRINGER JAPAN KK
DOI: 10.1007/s00535-016-1258-1
关键词
Liver cirrhosis; Mesenchymal stem cell; Macrophages; Cell therapy
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [26293175]
- Highway Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED)
- Grants-in-Aid for Scientific Research [26293175, 15K08990] Funding Source: KAKEN
The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; however, the characteristic features of this therapy differ from those of other treatments because of the involvement of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on the damaged liver, including alleviating liver cirrhosis and stimulating liver regeneration with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions appropriate for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据